Radiation of bilateral adrenal metastases is associated with a high risk of primary adrenal insufficiency.
Clin Endocrinol (Oxf)
; 99(1): 35-42, 2023 07.
Article
em En
| MEDLINE
| ID: mdl-36905107
ABSTRACT
BACKGROUND:
Adrenal metastasis is the most common adrenal malignancy and can be bilateral in up to 43% of patients. Radiotherapy (RT) is one option available to treat adrenal metastases. The risk of primary adrenal insufficiency (PAI) after adrenal RT is unclear.OBJECTIVE:
Determine the incidence and the timeline of PAI in patients undergoing adrenal RT. DESIGN, SETTING ANDPARTICIPANTS:
Single-centre longitudinal retrospective cohort study of adult patients with adrenal metastases treated with RT between 2010 and 2021.RESULTS:
Of 56 patients with adrenal metastases treated with adrenal RT, eight (14.3%) patients developed PAI at a median of 6.1 months (interquartile range [IQR] 3.9-13.8) after RT All patients developing PAI had either unilateral RT in the setting of contralateral adrenalectomy or bilateral adrenal RT. Patients who developed PAI received a median RT dose of 50 Gy (IQR 44-50 Gy), administered in a median of five fractions (IQR 5-6). Treated metastases decreased in size and/or metabolic activity on positron emission tomography in seven patients (87.5%). Patients were initiated on hydrocortisone (median daily dose of 20 mg, IQR 18-40) and fludrocortisone (median daily dose of 0.05 mg, IQR 0.05-0.05 mg). At the end of the study period, five patients died, all due to extra-adrenal malignancy, at a median time of 19.7 months (IQR 16-21.1 months) since RT and median time of 7.7 months (IQR 2.9-12.5 months) since the diagnosis of PAI.CONCLUSION:
Patients receiving unilateral adrenal RT with two intact adrenal glands have a low risk of PAI. Patients receiving bilateral adrenal RT have a high risk of PAI and require close monitoring.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Insuficiência Adrenal
/
Neoplasias das Glândulas Suprarrenais
/
Glândulas Suprarrenais
Tipo de estudo:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Clin Endocrinol (Oxf)
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Estados Unidos